Biogen Inc. or Viking Therapeutics, Inc.: Who Invests More in Innovation?

Biogen vs. Viking: A Decade of R&D Investment

__timestampBiogen Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014189342200022223073
Thursday, January 1, 201520128000006966842
Friday, January 1, 201619733000009000499
Sunday, January 1, 2017225360000013741186
Monday, January 1, 2018259720000019040000
Tuesday, January 1, 2019228060000023559000
Wednesday, January 1, 2020399090000031931000
Friday, January 1, 2021250120000044981000
Saturday, January 1, 2022223110000054234000
Sunday, January 1, 2023270260000063806000
Loading chart...

In pursuit of knowledge

Investing in Innovation: Biogen Inc. vs. Viking Therapeutics, Inc.

In the competitive world of biotechnology, innovation is the key to staying ahead. Biogen Inc. and Viking Therapeutics, Inc. are two companies that have consistently invested in research and development (R&D) to drive their growth. Over the past decade, Biogen has demonstrated a robust commitment to innovation, with R&D expenses peaking in 2020 at nearly double their 2014 levels. In contrast, Viking Therapeutics, while smaller in scale, has shown a steady increase in R&D spending, growing by approximately 187% from 2014 to 2023.

Biogen's R&D investment in 2023 was about 42 times greater than that of Viking Therapeutics, highlighting the scale of its operations. However, Viking's rapid growth in R&D spending reflects its ambition to expand its footprint in the biotech industry. As these companies continue to innovate, their investments in R&D will be crucial in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025